Fredun Pharmaceuticals Intrinsic Value
Fredun Pharmaceuticals (FREDUN) median intrinsic value is ₹1234.76 from 8 valuation models (range ₹564–₹2304), vs current price ₹2370.65 — -47.9% downside (Trading Above Calculated Value), margin of safety -92.0%. Also explore FREDUN share price charts to track price trends across different timeframes.
FREDUN Valuation Methods Summary — DCF, Graham Number & P/E
Fredun Pharmaceuticals intrinsic value across 8 models vs current price ₹2370.65 — upside/downside and value range per method. Browse Fredun Pharmaceuticals financial data for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1758.24 | ₹1406.59 - ₹2109.89 | -25.8% | EPS: ₹79.92, Sector P/E: 22x |
| Book Value Method | asset | ₹564.00 | ₹507.60 - ₹620.40 | -76.2% | Book Value/Share: ₹282.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2304.00 | ₹2073.60 - ₹2534.40 | -2.8% | Revenue/Share: ₹1152.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1680.00 | ₹1512.00 - ₹1848.00 | -29.1% | EBITDA: ₹84.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹711.20 | ₹640.08 - ₹782.32 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1234.76 | ₹1111.28 - ₹1358.24 | -47.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1185.33 | ₹1066.80 - ₹1303.86 | -50.0% | ROE: 25.5%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹711.20 | ₹640.08 - ₹782.32 | -70.0% | EPS: ₹79.92, BVPS: ₹282.00 |
FREDUN Intrinsic Value vs Market Price — All Valuation Models
Fredun Pharmaceuticals fair value range ₹564–₹2304 vs current market price ₹2370.65 across 8 valuation models. For current market price and key ratios, visit FREDUN share price screener.
FREDUN Intrinsic Value Analysis — Undervalued or Overvalued?
Fredun Pharmaceuticals median intrinsic value ₹1234.76, current price ₹2370.65 — Trading Above Calculated Value by 47.9%, margin of safety -92.0%.
What is the intrinsic value of FREDUN?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Fredun Pharmaceuticals (FREDUN) is ₹1234.76 (median value). With the current market price of ₹2370.65, this represents a -47.9% variance from our estimated fair value.
The valuation range spans from ₹564.00 to ₹2304.00, indicating ₹564.00 - ₹2304.00.
Is FREDUN undervalued or overvalued?
Based on our multi-method analysis, Fredun Pharmaceuticals (FREDUN) appears to be trading above calculated value by approximately 47.9%.
FREDUN Financial Health — Key Ratios vs Industry Benchmarks
Fredun Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 23.78 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 25.5% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.18x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
FREDUN Cash Flow Quality — Operating & Free Cash Flow
Fredun Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-29 Cr | ₹-32 Cr | Negative Cash Flow | 3/10 |